Active management of the third stage of labor: A brief overview of key issues/Dogumun ucuncu evresinin aktif yonetimi: Kilit konulara kisa bir bakis.
Postpartum hemorrhage (PPH) and blood loss complications constitute one of the most common causes of maternal mortality and morbidity. PPH is defined differently in various countries (Table 1) (1-4). Its incidence is 11% globally among women in labor (1-4). The third stage of labor (TSL) is defined as the time between the delivery of the baby and the expulsion of the placenta. The duration of the third stage is -6-30 minute (3,4). The pathophysiology of the TSL is still not fully understood. During this stage, expulsion of placenta with the formation of capillary hemorrhage after the birth of the baby is followed by shrinking of the placental surface with uterine contractions, and finally ends with the discharge of the placenta from the uterus. Hemorrhage is restricted with uterine contractions and activation of the coagulation system (2,4). As can be understood from this definition, some degree of hemorrhage always occurs at this stage (~100-250 cc). It is important to limit the amount of hemorrhage to the minimum possible level. Accordingly, the World Health Organization (WHO) suggested the active management of the TSL (Table 2) (3).
1) Oxytocin: Oxytocin is the most commonly used agent and the primary drug of choice in the TSL. Oxytocin's action is unique to the smooth muscles of the uterus; it increases the amplitude and frequency of contractions. Oxytocin binds to a G-protein on the surface of uterine myocytes, resulting in the generation of diacylglycerol (DAG) and inositol triphosphate (IP3) via the action of phospholipase C on phosphatidylinositol bisphosphate. DAG stimulates PG synthesis, and IP3 stimulates the release of calcium from the sarcoplasmic reticulum. It also activates cyclooxygenase 2 by a further G-protein interaction and, in doing so, stimulates PG synthesis.
Oxytocin can be used just after delivery of the front shoulder of the baby or expulsion of the placenta. Generally, its administration route and dose are 10 IU intramuscularly (IM). It can also be used intravenously (IV), which is typically preferred during cesarean sections (CS). A newly developed oxytocin tablet has recently been presented that can be applied successfully via the sublingual route (5). An in vitro study showed a >30% reduction in tissue transepithelial electrical resistance after treatment with the oxytocin fast-dissolving tablet, implying an increase in the permeability of the mucosal tissue to oxytocin (5). However, it may cause ST depression on an electrocardiogram and hypotension. The efficacy of oxytocin is the same with both administration routes. In a 600-patient study from Turkey, there was no statistically significant difference in the amount of postpartum blood loss between IM and IV administration (6). Oxytocin also decreased postpartum blood loss when applied inside the placental cord (7).
2) Ergometrine (methergine): Ergot alkaloids exert various effects throughout the body on at least three different types of receptor. They are non-selective 5-hydroxytryptamine 1 agonists and have affinities for dopamine and noradrenalin receptors. Ergot alkaloids are absorbed rapidly and completely after oral administration. Both are usually effective within 1-5 min after an IM injection. They are metabolized in the liver, and reported half-lives range from 0.5 to 2 h. Their actions on the uterus are probably a result of their agonist properties against adrenergic [alpha]-receptors; these receptors, when stimulated, lead to IP3 release and to calcium mobilization from the sarcoplasmic reticulum. To date, there is only one prospective study in the English literature on this topic. In that study, the authors compared the efficacy of rectal misoprostol 400 [micro]g, oxytocin 10 IU injected IM, methylergometrine 0.2 mg injected I V, and 0.5 mg ergometrine +5 IU oxytocin injected IM in reducing blood loss in the TSL. They found that methylergometrine had the "best" uterotonic drug profile (lowest blood loss during the third stage and duration of the TSL). However, the study had several limitations. Most importantly, it was not a randomized study, the trial was not double-blinded, leading to the possibility of biased results, and no power calculation was reported (8). Ergometrine causes continuous contraction of the uterus. There is not enough evidence about its use as a single agent. It is typically administered at 0.2 mg IM. Its use must be avoided in patients with hypertension.
3) Syntometrine: This contains 5 IU oxytocin and 0.5 mg ergometrine. The time of onset of the uterine response after IM administration is shorter than after ergometrine alone, and the duration of action is several hours. Although it was found to be more effective than oxytocin in a review, the adverse effect profile (hypertension, nausea, vomiting) restricts its use (9).
4) Misoprostol: This is a synthetic prostaglandin E1 derivative. It is an inexpensive drug and is stored readily. It does not cause high blood pressure and can be used in patients with asthma. Its most common adverse effect is flushing. Although the amount of blood loss has been shown to have been reduced with prophylactic use of misoprostol in many studies, it is not as effective as oxytocin. Consequently, oxytocin is the first choice for the prophylaxis of PPH (10-12). In countries where the socioeconomic level is very low and home deliveries are common, misoprostol can be used as the first-line drug; it can be used orally, rectally or sublingually. The route of administration and dose differ from country to country. The WHO and International Federation of Gynaecology and Obstetrics recommend a single dose of 600 [micro]g misoprostol, oral or sublingual, for the prophylaxis of PPH (13). According to a recently published meta-analysis result, misoprostol has been used in the third stage of labor to prevent PPH when a sterile syringe and trained midwife were absent (14). In a prospective randomized trial published in 2016, it was shown that the additional use of buccal misoprostol in conjunction with active management of the TSL reduced the need for additional uterotonic drugs (15).
5) Tranexamic acid: Tranexamic acid (TA) is a lysine derivative with anti-fibrinolytic activity that inhibits fibrin degradation by blocking lysine-binding regions on plasminogen. TA is absorbed from the gastrointestinal tract at 30-40% (16,17). Its plasma half-life is 2 h, and its plasma protein binding ratio is ~3%, which is solely a result of plasminogen binding. It can cross the placenta and be passed to a breastfeeding infant. It is excreted through the urine, so it must be avoided in patients with renal failure. It can be used in an oral, local or parenteral manner. It is typically a well-tolerated drug. Rarely, it may cause nausea, vomiting, hypotension, and dizziness (17,18). These adverse effects are more common when it is given parenterally at high flow rates. One gram of IV TA given within 3 hours of PPH was reported to significantly reduce maternal death and the need for surgery (19). In pill form, it is recommended at a 15-25 mg/kg/dosage every 8 h orally for 5-10 days. There may be gastrointestinal adverse effects. The maximum dose is 3-4 g. It should be given at 10 mg/kg/dosage (maximum 500 mg) with slow infusion every 8 h when given parenterally. Activated prothrombin complex concentrates must be avoided (17,18). Using TA for the treatment of PPH, the incremental cost-effectiveness ratios were found below the lower bound of the cost-effectiveness threshold range (20).
- Tranexamic acid for the prevention of postpartum hemorrhage after cesarean section
There are 11 randomized controlled trials (RCT) about this topic in the literature (21-31). Except in one study, elective CSs were performed in all patients. In all studies, the amount of blood loss decreased with the use of TA and no adverse effects were reported. The first large study was reported by Gungorduk et al. (24) from Bakirkoy Women and Children's Hospital in 2011. In total, 660 patients were included in the study and a decrease in the amount of blood loss was seen after the routine administration of 5 IU oxytocin following 20 IU oxytocin in 500 ml RL and TA (1 g IV in 5 min) at the third stage of labor; no adverse effects were reported (24). Another study with 740 patients reported similar results in 2013 (29). As can be seen from the results of these studies, administration of TA as an additional agent in the TSL decreased the blood loss.
- Tranexamic acid for the prevention of prevention of postpartum hemorrhage after vaginal delivery
There are three RCTs on this topic in the literature (24-32). Yang et al. (32) administered 10 IU oxytocin 10 min after delivery of TA in their study. They reported that TA decreased the incidence of PPH. In a study published in 2013 from Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey, the TSL was managed actively in all patients. An additional 1 g TA was given to a group of patients in this study. At the end of the study, less blood loss and a lower incidence of PPH was reported in the group using TA (24). Mirghafourvand et al. (33) reported that administration of 1 g TA after 10 IU oxytocin decreased PPH in a study of 120 pregnant women in 2015. In conclusion, TA decreases the amount of blood loss and the incidence of PPH in patients who are managed actively in the TSL.
Tranexamic acid adverse effects
In a previous study, the risks of myocardial infarction, cerebrovascular stroke, deep vein thrombosis, and pulmonary embolus were not statistically significantly increased compared with a control group (16). The most common adverse effects are nausea and vomiting. Two patients experienced thromboemboli when receiving high-dose TA in the EXADELI study (34). There is only one reported RCT concerning neonatal adverse effects in the postpartum period. No adverse effects related with TA was reported in this study (24). However, the design of the study was inadequate to assess neonatal adverse effects. It can cross the placenta, so there is a need for large studies with administration before cord clamping.
Route of administration for uterotonic agents
Although the standard doses of uterotonic agents are given above, the actual dose and administration forms differ in various countries. Table 3 lists four common international guidelines for dose and administration (29,35).
Delivery of placenta with controlled cord traction
Although this was recommended in the 2007 WHO guidelines, it is described as optional for the active management of the third stage in the 2012 updated guidelines (13). An inexperienced operator may cause serious complications, such as uterine inversion. In WHO studies, it was accepted as ineffective for decreasing blood loss. However, according to a meta-analysis reported in 2015, although the risk of blood loss above 1000 mL was not decreased with controlled cord traction, the mean time of the third stage, the mean blood loss (less than 10 mL), and the risk of blood loss less than 500 mL were all decreased (36). The authors noted that controlled cord traction still had a place in active management when performed by experienced personnel. It is also a recommended method for CSs (24,37).
Uterine fundal massage after placental expulsion
Uterine fundal massage after placental expulsion provides uterine contractions by stimulating endogenous prostaglandin secretion. This method was recommended in the 2007 WHO guidelines, and was described as optional for the active management of the third stage in the 2012 updated guidelines (13). Similarly, Chen et al. (38) published results of a study of 2340 pregnancies, which showed that the addition of fundal massage to oxytocin did not decrease PPH.
Possible adverse effects of active management
Adverse effects related to uterotonic agents
- Hypertension, nausea, vomiting due to ergot alkaloids
Risk of placental retention
Neonatal risks related to early cord clamping
- Iron-deficiency anemia
- Intraventricular hemorrhage
According to the most recent Cochrane analysis, active management of the TSL decreases the risk of postpartum bleeding of over 1000 mL (39). The possible risks and benefits of active management must be explained to pregnant women and informed consent must be obtained. TA administration, as an extra drug for pregnant women whose TSL is being managed actively, decreases both the amount of blood loss and the incidence of PPH.
Peer-review: Externally peer-reviewed.
Concept: Y.O., Design: Y.O., Literature Search: V.G., M.K., Writing: K.G.
Conflict of Interest: No conflict of interest was declared by the authors.
Financial Disclosure: The authors declared that this study received no financial support.
(1.) American College of Obstetricians and Gynecologists. ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 76, October 2006: postpartum hemorrhage. Obstet Gynecol 2006;108:1039-47.
(2.) Rath WH. Postpartum hemorrhage- update on problems of definitions and diagnosis. Acta Obstet Gynecol Scand 2011:90:421-28.
(3.) World Health Organization WHO guidelines for the management of postpartum haemorrhage and retained placenta. Geneva: World Health Organization; 2009.
(4.) Royal College of Obstetrician and Gynaecologists. Postpartum Hemorrhage: Prevention and Management; 2011.
(5.) Zhu C, Estrada M, White J, Lal M. Heat-stable sublingual oxytocin tablets as a potential needle-free approach for preventing postpartum hemorrhage in low-resource settings. Drug Deliv Transl Res 2018;8:853-6.
(6.) Oguz Orhan E, Dilbaz B, Aksakal SE, Altinbas S, Erkaya S. Prospective randomized trial of oxytocin administration for active management of the third stage of labor. Int J Gynecol Obstet 2014;127:175-9.
(7.) Gungorduk K, Asicioglu O, Besimoglu B, Gungorduk OC, Yildirm G, Ark C, et al. Using intraumbilical vein injection of oxytocin in routine practice with active management of the third stage of labor: a randomized controlled trial. Obstet Gynecol 2010;116:619-24.
(8.) Gohil JT, Tripathi B. A Study to Compare the Efficacy of Misoprostol, Oxytocin, Methyl-ergometrine and Ergometrine-Oxytocin in Reducing Blood Loss in Active Management of 3rd Stage of Labor. J Obstet Gynaecol India 2011;61:408-12.
(9.) McDonald SJ, Abbott JM, Higgins S P. Prophylactic ergometrine-oxytocin versus oxytocin for the third stage of labour. Cochrane Database Syst Rev 2004:CD000201.
(10.) Mobeen N, Durocher J, Zuberi N, Jahan N, Blum J, Wasim S, et al. Administration of misoprostol by trained traditional birth attendants to prevent postpartum haemorrhage in homebirths in Pakistan: a randomised placebo-controlled trial. BJOG 2011;118:353-61.
(11.) Gulmezoglu AM, Villar J, Ngoc NT, Piaggio G, Carroli G, Adetoro L, et al. WHO multicentre randomised trial of misoprostol in the management of the third stage of labour. Lancet 2001;358:689-95.
(12.) Tuncalp O, Hofmeyr GJ, Gulmezoglu AM. Prostaglandins for preventing postpartum haemorrhage. Cochrane Database Syst Rev 2012:CD000494.
(13.) WHO Recommendations for the Prevention and Treatment of Postpartum Haemorrhage. Geneva: World Health Organization; 2012.
(14.) Tan J, Cao Q, He GL, Cai YH, Yu JJ, Sun X, et al. Misoprostol versus ergometrine-oxytocin for preventing postpartum haemorrhage: a systematic review and meta-analysis of randomized controlled trials. J Evid Based Med 2016;9:194-204.
(15.) Hernandez-Castro F, Lopez-Serna N, Trevino-Salinas EM, Soria-Lopez JA, Sordia-Hernandez LH, Cardenas-Estrada E. Randomized double-blind placebo-controlled trial of buccal misoprostol to reduce the need for additional uterotonic drugs during cesarean delivery. Int J Gynaecol Obstet 2016;132:184-7.
(16.) Sentilhes L, Lasocki S, Ducloy-Bouthors AS, Deruelle P, Dreyfus M, Perrotin F, et al. Tranexamic acid for the prevention and treatment of postpartum haemorrhage. Br J Anaesth 2015;114:576-87.
(17.) Draxler D F, Medcalf RL. The Fibrinolytic System-More Than Fibrinolysis? Transfus Med Rev 2015;29:102-9.
(18.) Tengborn L, Blomback M, Berntorp E. Tranexamic acid--an old drug still going strong and making a revival. Thromb Res 2015;135:231-42.
(19.) Hinshaw K. Tranexamic acid for post-partum haemorrhage in the WOMAN trial. Lancet 2017;390:1582-3.
(20.) Li B, Miners A, Shakur H, Roberts I; WOMAN Trial Collaborators. Tranexamic acid for treatment of women with post-partum haemorrhage in Nigeria and Pakistan: a cost-effectiveness analysis of data from the WOMAN trial. Lancet Glob Health 2018;6:222-8.
(21.) Gai M, Wu L, Su Q, Tatsumoto K. Clinical observation of blood loss reduced by tranexamic acid during and after caesarean section: a multi-center, randomized trial. Eur J Obstet Gynecol Reprod Biol 2004;112:154-7.
(22.) Mayur G, Purvi P, Ashoo G, Pankaj D. Efficacy of tranexamic acid in decreasing blood loss during and after caesarean section: a randomized case controlled prospective study. J Obstet Gynecol India 2007;57:227-30.
(23.) Sekhavat L, Tabatabaii A, Dalili M, Farajkhoda T, Tafti A D. Efficacy of tranexamic acid in reducing blood loss after caesarean section. J Matern Fetal Neonatal Med 2009;22:72-5.
(24.) Gungorduk K, Yildirim G, Asicioglu O, Gungorduk OC, Sudolmus S, Ark C. Efficacy of intravenous tranexamic acid in reducing blood loss after elective cesarean section: a prospective, randomized, double-blind, placebo-controlled study. Am J Perinatol 2011;28:233-40.
(25.) Movafegh A, Eslamian L, Dorabadi A. Effect of intravenous tranexamic acid administration on blood loss during and after caesarean delivery. Int J Gynecol Obstet 2011;115:224-6.
(26.) Xu J, GaoW, Ju Y. Tranexamic acid for the prevention of postpartum haemorrhage after caesarean section: a double-blind randomization trial. Arch Gynecol Obstet 2013;287:463-8.
(27.) Senturk MB, Cakmak Y, Yildiz G, Yildiz P. Tranexamic acid for caesarean section: a double-blind, placebo-controlled, randomized clinical trial. Arch Gynecol Obstet 2013;287: 641-5.
(28.) Shahid A, Khan A. Tranexamic acid in decreasing blood loss during and after caesarean section. J Coll Physicians Surg 2013;23:459-62.
(29.) Abdel-Aleem H, Alhusaini TK, Abdel-Aleem MA, Menoufy M, Gulmezoglu AM. Effectiveness of tranexamic acid on blood loss in patients undergoing elective caesarean section: randomized clinical trial. J Matern Fetal Neonatal Med 2013;26:1705-9.
(30.) Goswami U, Sarangi S, Gupta S, Babbar S. Comparative evaluation of two doses of tranexamic acid used prophylactically in anemic parturients for lower segment caesarean section: A double-blind randomized case control prospective trial. Saudi J Anaesth 2013;7:427-31.
(31.) Ahmed MR, Sayed Ahmed WA, Madny EH, Arafa AM, Said MM. Efficacy of tranexamic acid in decreasing blood loss in elective caesarean delivery. J Matern Fetal Neonatal Med 2015;28:1014-8.
(32.) Yang H, Zheng S, Shi C. Clinical study on the efficacy of tranexamic acid in reducing postpartum blood lose: a randomized, comparative, multicenter trial. Zhonghua Fu Chan Ke Za Zhi 2001;36:590-2.
(33.) Mirghafourvand M, Mohammad-Alizadeh S, Abbasalizadeh F, Shirdel M. The effect of prophylactic intravenous tranexamic acid on blood loss after vaginal delivery in women at low risk of postpartum haemorrhage: a double-blind randomised controlled trial. Aust N Z J Obstet Gynaecol 2015;55:53-8.
(34.) Ducloy-Bouthors AS, Jude B, Duhamel A, Huissoud C, Keita-Meyer H, Mandelbrot L, et al. High-dose tranexamic acid reduces blood loss in postpartum haemorrhage. Crit Care 2011;15:117.
(35.) Gungorduk K, Asicioglu O, Yildirim G, Ark C, Tekirdag AI, Besimoglu B. Can intravenous injection of tranexamic acid be used in routine practice with active management of the third stage of labor in vaginal delivery? A randomized controlled study. Am J Perinatol 2013;230:407-13.
(36.) Hofmeyr GJ, Mshweshwe NT, Gulmezoglu AM. Controlled cord traction for the third stage of labour. Cochrane Database Syst Rev 2015:1:CD008020.
(37.) Gungorduk K, Asicioglu O, Celikkol O, Olgac Y, Ark C. Use of additional oxytocin to reduce blood loss at elective caesarean section: A randomised control trial. Austr N Z J Obstet Gynaecol 2010;50:36-9.
(38.) Chen M, Chang Q, Duan T, He J, Zhang L, Liu X. Uterine massage to reduce blood loss after vaginal delivery: a randomized controlled trial. Obstet Gynecol 2013;122:290-5.
(39.) Begley CM, Gyte GM, Devane D, McGuire W, Weeks A. Active versus expectant management for women in the third stage of labour. Cochrane Database of Syst Rev 2015:CD007412.
[iD] Kemal Gungorduk (1), [iD] Yusuf Olgac (2), [iD] Varol Gulseren (3), [iD] Mustafa Kocaer (4)
(1) Mugla Sitki Kocman University, Training and Research Hospital, Clinic of Gynecology and Oncology, Mugia, Turkey
(2) Bilim University Faculty of Medicine, Department of Obstetrics and Gynecology, Istanbul, Turkey
(3) Kaman State Hospital, Clinic of Obstetrics and Gynecology, Kirsehir, Turkey
(4) University of Health Sciences, Izmir Tepecik Training and Research Hospital, Department of Obstetrics and Gynecology, Izmir, Turkey
Address for Correspondence/Yazisma Adresi: Kemal Gungorduk, MD, Mugia Sitki Kocman University Training and Research Hospital, Clinic of Gynecology and Oncology, Mugla, Turkey
Phone: +90 505 492 17 66 E-mail: email@example.com ORCID ID: orcid.org/0000-0002-2325-1756
Received/Gelis Tarihi: 08.03.2018
Accepted/Kabul Tarihi: 08.05.2018
Table 1. Post-partum hemorrhage definitions Country Definition Australia 2008 Amount of blood loss: >500 mL at vaginal birth, >750 mL at cesarean section Austria 2008 Amount of blood loss between 500-1000 mL + clinical symptoms of hypovolemic shock or amount of blood loss >1000 mL Germany 2008 Amount of blood loss during first 24 h after birth [greater than or equal to]500 mL, serious PPH blood loss during first 24 h after birth [greater than or equal to]1000 mL Royal College of Obstetrics Amount of blood loss of 500-1000 mL and absence of clinical symptoms of hypovolemic shock and Gynecology, United Amount of blood loss [greater than or equal to]1000 mL or presence of clinical symptoms of hypovolemic shock Kingdom World Health Organization Amount of blood loss during first 24 h after birth [greater than or equal to]500 mL, serious PPH blood loss during first 24 h after birth [greater than or equal to]1000 mL Table 2. Active management of the third stage of labor a) Administration of uterotonic agents after delivery of the baby b) Expulsion of placenta with controlled traction of cord c) Uterine fundal massage after expulsion of placenta Table 3. Drug doses and administration forms in four major international guidelines ACOG RANZCOG Oxytocin 10-40 IU IV or 10 IU IM Not specified Ergots Metilergonavin 0.2 mg Not specified IM per 24 h period Misoprostol 800-1000 [micro]g rectal 1000 [micro]g rectal Tranexamic acid - - RCOG Oxytocin 5 IU IV (repeatable) or 40 IU IV 125 mL/h in 500 mL Ergots Ergometrin 0.5 mg IV or IM Misoprostol 1000 [micro]g rectal Tranexamic acid Not suggested SCOG Oxytocin 10 IU IM or 5 IU IV or 40 IU IV 125 mL/h in 500 mL Ergots Ergonovin 0.25 mg IV or IM every 2 h Misoprostol 400-1000 [micro]g oral or rectal Tranexamic acid Not suggested ACOG: American Congress of Obstetrics and Gynecology, RANZCOG: Royal Australian and New Zealand Congress of Obstetrics and Gynecology, RCOG: Royal Congress of Obstetrics and Gynecology, SCOG: Canadian Society of Obstetrics and Gynecology, IV: Intravenous, IM: Intramuscular